Liu, NanZhang, LeiWang, ZhenCheng, YingduanZhang, PengxingWang, XinWen, WeihongYang, HongweiLiu, HuiJin, WeilinZhang, YongshengTu, Yanyang2017-05-012017Liu, N., L. Zhang, Z. Wang, Y. Cheng, P. Zhang, X. Wang, W. Wen, et al. 2017. “MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9.” Oncotarget 8 (12): 19244-19254. doi:10.18632/oncotarget.13706. http://dx.doi.org/10.18632/oncotarget.13706.http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630582Glioblastoma multiforme (GBM) is the most common primary malignant tumors originating in the brain parenchyma. At present, GBM patients have a poor prognosis despite the continuous progress in therapeutic technologies including surgery, radiotherapy, photodynamic therapy, and chemotherapy. Recent studies revealed that miR-101 was remarkably down-regulated in kinds of human cancers and was associated with aggressive tumor cell proliferation and stem cell self-renewal. Data also showed that miR-101 was down-regulated in primary glioma samples and cell lines, but the underlying molecular mechanism of the deregulation of miR-101 in glioma remained largely unknown. In this study, we found that miR-101 could inhibit the proliferation and invasion of glioma cells both in vitro and in vivo by directly targeting SOX9 [sex-determining region Y (SRY)-box9 protein]. Silencing of SOX9 exerted similar effects with miR-101 overexpression on glioma cells proliferation and invasion. Quantitative reverse transcription PCR and Western blotting analysis revealed a negative relationship between miR-101 and SOX9 in human glioma U251MG and U87MG cells, and the luciferase assay indicated that miR-101 altered SOX9 expression by directly targeting on 3′UTR. Taken together, our findings suggest that miR-101 regulates glioma proliferation, migration and invasion via directly down-regulating SOX9 both in vitro and in vivo, and miR-101 may be a potential therapeutic target for future glioma treatment.en-USMiR-101SOX9invasionmigrationproliferationJournal Article2017-05-0110.18632/oncotarget.13706